Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 16th Jan 2020 12:58
(Sharecast News) - Diageo: Jefferies downgrades to hold with a target price of 3,600p

Auto Trader: Credit Suisse reiterates underperform with a target price of 480p.

Coca-Cola: Deutsche Bank reiterates buy with a target price of 3,100p.

AstraZeneca: Barclays reiterates overweight with a target price of 8,500p.

IQE: Barclays downgrades to equal weight with a target price of 55p.

Spirent Communications: Barclays downgrades to underweight with a target price of 190p.

Gamma Communications: Barclays reiterates overweight with a target price of 1,350p.

GlaxoSmithKline: Credit Suisse reiterates neutral with a target price of 1,860p.

4imprint Group: Peel Hunt downgrades to hold with a target price of 3,250p.

Brown N Group: Peel Hunt downgrades to hold with a target price of 150p.

Tullow Oil: Barclays downgrades to equal weight with a target price of 75p.

Electrocomponents: JP Morgan upgrades to overweight with a target price of 774p.

BAE Systems: JP Morgan upgrades to overweight with a target price of 715p.

Vodafone: Goldman Sachs initiates at buy with a target price of 190p. Tullow Oil Astrazeneca 4Imprint Gamma Communications Auto Trader BAE Systems Diageo Vodafone Coca-Cola HBC IQE Glaxosmithkline

Shares in this article

Related News

LONDON MARKET CLOSE: Vodafone lifts FTSE 100 as easyJet backs new bid
2 hours ago

LONDON MARKET CLOSE: Vodafone lifts FTSE 100 as easyJet backs new bid

(Alliance News) - The FTSE 100 closed higher on Friday in calmer trading, boosted by double-digit gains from telecommunications firm Vodafone.

Market News Vodafone + 12 more shares
German lawmakers approve healthcare shake-up aimed at taming costs
3 hours ago

German lawmakers approve healthcare shake-up aimed at taming costs

* Legislation seeks to rein in rising health insurance costs

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
4 hours ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug